All In Biotech

Drug Trial Radar · NCT05524545

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Nov 2, 2022

Primary completion

Jun 27, 2025

Study completion Jun 27, 2025

Sponsor

Lead sponsor
ALX Oncology Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.

Conditions

  • Bladder Cancer
  • Urothelial Carcinoma

Interventions

  • EvorpaceptDrug

    Fusion protein that blocks CD47-SIRPalpha pathway

  • Enfortumab VedotinDrug

    Nectin-4 directed antibody and microtubule inhibitor conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First Cycle Dose limiting toxicities (DLTs)Time frame: Up to 28 days
  2. Adverse Events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0)), timing, seriousness, and relationship to study therapyTime frame: Up to 24 months
  3. Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Up to 15 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida

  • Massachusett's General

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Oregon Health & Science University

    Portland, Oregon

  • West Clinic

    Germantown, Tennessee

  • UT Southwestern

    Dallas, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.